

**Our mission is simple and powerful: we are committed to discovering, developing, and commercializing effective, safe and well-tolerated, oral and convenient, affordable medicines for billions of people around the world.**

## Company Overview

Evelo is a clinical stage biotechnology company focused on harnessing the central biology of the small intestine to develop a new class of effective, safe and well-tolerated, oral and convenient, affordable medicines with the potential to treat billions of people at all stages of inflammatory disease.

**Ticker Symbol:** EVLO

**Employees:** ~130

**Founded:** 2015

**Headquarters:** Cambridge, MA

## The Small Intestine is a Big Deal

### The power of targeting SINTAX

The small intestinal axis, SINTAX, is the network of connections that has evolved to link the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate our immune, metabolic, and neurological systems.

We are discovering and developing a new class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Our gut-restricted medicines are selected for their ability to modulate SINTAX.

## Our Product Candidates

### A new class of oral medicine

Evelo's orally delivered product candidates are pharmaceutical compositions of single strains of microbes or microbial extracellular vesicles (EVs) selected for their ability to modulate the immune system through SINTAX. Our product candidates are non-replicating – in clinical and preclinical studies, Evelo has observed that these product candidates do not colonize the gut or modify the microbiome, and they are not absorbed into the body.

Data from Phase 1 and 2 trials of EDP1815 in psoriasis showed that Evelo's SINTAX product candidate was well tolerated, had safety data generally comparable to placebo, and had clinically meaningful effects. Evelo believes this is driven by direct interaction between immune and epithelial cells in the small intestine with structural motifs on the surface of SINTAX medicines. Our platform and product candidates have the potential to target diseases ranging from inflammatory conditions such as psoriasis, atopic dermatitis, asthma, arthritis, inflammatory bowel disease, and food allergy, to neuroinflammatory conditions such as multiple sclerosis, and possibly Parkinson's and Alzheimer's disease.

# Our Product Candidates


## A new class of oral medicine

Evelo is building a pipeline of product candidates in multiple therapeutic areas where SINTAX-based medicines can have the greatest impact on people living with inflammatory diseases. More than one billion people worldwide suffer from chronic inflammatory diseases. Because of the limitations of treatments that are currently available, many of these people are undertreated or not treated at all. Evelo's product candidates have the potential to address unmet need for these patients.

The Company currently has two products in clinical development: EDP1815 and EDP2939 for the treatment of inflammatory diseases.

The Company is also working to harness the ability of microbial EVs to influence the immune system via SINTAX. Preclinically, these EVs have been observed to show potential to treat inflammatory diseases and cancer.

## Late Stage Clinical Pipeline



\*Data from first 3 cohorts in Phase 2 trial.  
+ Data from 4<sup>th</sup> cohort in Phase 2 trial.

## Leadership Team

**Simba Gill, Ph.D.**, CEO  
**Stu Abel, Ph.D.**, Global Head of Regulatory Affairs, EU Head of Clinical Development  
**Mark Bodmer, Ph.D.**, Chief Scientific Officer  
**Julie Carretero**, Chief People Officer  
**Daniel S. Char, J.D.**, General Counsel  
**Andrea Itano, Ph.D.**, Head of Research  
**Duncan McHale, M.B.B.S., Ph.D.**, Chief Medical Officer  
**Mark Plinio, J.D.**, Chief Commercial Officer  
**Marella Thorell**, Chief Financial Officer  
**Leslie Wardwell-Scott, Ph.D.**, Head of Corporate Development and Strategic Integration  
**Chun Zhang, Ph.D.**, Chief Technical Operations and Quality Officer  
**Jonathan Zung, Ph.D.**, Chief Development Officer

## Board of Directors

**Professor the Lord Ara Darzi**, Chairman  
**Simba Gill, Ph.D.** CEO  
**Juan Andres**  
**David R. Epstein**  
**Jose-Carlos Gutiérrez—Ramos, Ph.D.**,  
**John Hohneker, M.D.**  
**Julie McHugh**  
**Iain McInnes, B.Sc, M.B.Ch.B, Ph.D.**  
**Theodose Melas-Kyriazi**  
**Tonya Williams, J.D.**